MedTrace Logo

Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus

NCT01299012 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2017-02-09

No results posted yet for this study

Summary

Evaluating the use of Liraglutide in patients with Type 1 Diabetes.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Liraglutide

Liraglutide s/c 0.6mg once daily.

Sponsors & Collaborators

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Paresh Dandona · University at Buffalo

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-02-28
Completion
2013-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01299012 on ClinicalTrials.gov